


09

11

At a Glance


Profile HBM BioVentures invests in the health-care sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/ human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on

financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM BioVentures an interesting alternative to investing in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).




Allocation of assets¹⁾

Mainly invested in private companies with high value-creation potential.




Currency allocation of net assets¹⁾

Emphasis on US dollar investments.



Development phase of portfolio companies²⁾

Largely invested in profitable companies or in companies with products available on the market.



Therapeutic area of the lead products of portfolio companies²⁾

Broadly diversified areas of activity.

1) Total assets as at 30.9.2011: CHF 531 million (pro forma, after repayment of bonds in December 2011)

2) Total investments as at 30.9.2011: CHF 391 million

Key Figures, Performance and the ten largest Investments

| Key Figures | | 30.9.2011 | 31.3.2011 | 31.3.2010 | 31.3.2009 | 31.3.2008 |
|--|-----------------------|---------------|---------------|---------------|---------------|---------------|
| Net assets | CHF million | 523.9 | 589.2 | 666.1 | 618.9 | 948.3 |
| Investments in private companies | | 279.0 | 367.6 | 532.6 | 594.5 | 685.0 |
| Investments in public companies | | 111.7 | 83.4 | 100.3 | 132.0 | 311.7 |
| Cash and cash equivalents | | 132.1 | 155.8 | 129.1 | 65.6 | 86.8 |
| Net cash flow from investing activities | CHF million | 0.5 | 148.9 | 186.9 | 27.9 | 83.5 |
| Net result for the period/for the year | CHF million | -49.7 | -56.4 | 66.0 | -312.9 | -222.3 |
| Basic earnings per share | CHF | -5.22 | -5.73 | 6.39 | -28.98 | -19.90 |
| Net asset value (NAV) per share | CHF | 56.34 | 61.15 | 65.85 | 58.80 | 86.60 |
| Share price | CHF | 41.30 | 44.60 | 49.50 | 22.00 | 68.95 |
| Discount | | -26.7% | -27.1% | -24.8% | -62.6% | -20.4% |
| Shares issued | Registered shares (m) | 9.8 | 10.2 | 10.7 | 11.3 | 11.3 |
| Shares outstanding | Registered shares (m) | 9.3 | 9.6 | 10.1 | 10.5 | 11.0 |

| Performance | Quarter | Calendar Year | 12 months | since start of business (12.7.2001) |
|--|---------|---------------|-----------|-------------------------------------|
| HBM BioVentures Ltd | | | | |
| Net asset value (NAV) | -2.6% | -3.0% | -8.0% | -44.2% |
| Registered share HBMN | -16.6% | -2.8% | 2.5% | -59.1% |
| Relevant market indices in Swiss francs | | | | |
| Nasdaq Biotech Index (NBI) | -5.5% | -2.9% | 0.1% | -42.7% |
| MSCI World Pharma Index | -1.2% | -2.9% | -7.2% | -53.0% |

| The 10 largest investments as at 30.9.2011 ¹⁾ | | Fair value (CHF 000) | As % of net assets |
|--|--|----------------------|--------------------|
| Private companies | | | |
| Cathay Industrial Biotech | | 25,430 | 4.9% |
| PTC Therapeutics | | 21,981 | 4.2% |
| Lux Biosciences | | 18,749 | 3.6% |
| ChemoCentryx | | 15,579 | 3.0% |
| Ophthotech | | 14,947 | 2.9% |
| Nabriva Therapeutics | | 13,796 | 2.6% |
| Interventional Spine | | 13,733 | 2.6% |
| Probiodrug | | 7,647 | 1.5% |
| Public companies | | | |
| Basilea Pharmaceutica ^{P)} | | 67,156 | 12.8% |
| Pacira Pharmaceuticals ^{P)} | | 28,296 | 5.4% |

P) Position originating from the private companies portfolio.

1) Excluding venture capital funds.

Dear Shareholders

The successful sale of the German portfolio company mtm laboratories to Roche was the outstanding achievement during the quarter under review. At EUR 47 million, the provisional proceeds from this sale represent double HBM BioVentures' investment in mtm laboratories. If future study data are positive, HBM BioVentures stands to receive additional performance-related milestone payments of up to EUR 21 million. Even if these payments are valued conservatively, the annualised return on the mtm laboratories investment comes to 19%. The positive business and value growth achieved by mtm laboratories, as well as its successful sale, are due in part to many years of close cooperation between various HBM experts and the management of mtm laboratories.

«The proceeds from the sale of mtm laboratories represent **double** HBM BioVentures' investment.»

The proceeds from the sale of mtm laboratories further strengthened HBM BioVentures' cash position. Factoring in the repayment of the CHF 30 million bond that is due in December 2011, as at the end of September 2011 cash and cash equivalents accounted for 19% of net assets, while the net equity ratio reached a high 99%. 53% of assets are invested in private companies (38% directly and 15% indirectly), 21% in public companies, and 7% is accounted for by discounted possible future milestone payments. These are weighted according to the probability of their occurrence, and could potentially be much higher if the companies in question perform well.

The quarter under review was characterised by unprecedented exchange rate volatility and the sharp drop on the equity markets at the beginning of August. Combined with the marked strength of the Swiss franc, these events accentuated swings in HBM BioVentures' net asset value (NAV), despite the partial hedge of USD risk. The USD hedging arrangement has so far proven to be the right one for the Company. It protects against a collapse of the USD, without limiting the positive effect of its potential appreciation on NAV. HBM BioVentures reported net currency gains of CHF 11 million for the reporting period. EUR foreign exchange risks are not hedged at present.

The quarter under review saw significant expansion in our holding in the biotechnology company Basilea. HBM BioVentures firmly believes that, at current share prices, Basilea is significantly undervalued. Its current position as Basilea's largest investor permits HBM BioVentures to present its views on the company's strategic direction to Basilea's Board of Directors and management. Data from the final trial of Toctino, a product already available on the European market, are expected in the coming months. If successful, they could be used to apply for Toctino to be approved for the treatment

of hand eczema in the US. The results of a renewed analysis of data on the Ceftobiprole antibiotic from clinical studies involving patients with pneumonia will be presented towards the end of 2011/early 2012. In the best-case scenario, the quality of these data will lead to an application to approve Ceftobiprole for the treatment of lung infections, or at least clarify whether or not further clinical studies must be conducted before an application for approval can be submitted. The Isavuconazole anti-fungal molecule is being tested by partner Astellas in a variety of phase III clinical studies. Meanwhile, BAL30072, which is effective against gram-negative bacteria, is currently undergoing its second phase I study. The performance of HBM BioVentures' investment in Pacira will be heavily influenced by the FDA's licensing decision on Pacira's post-operative pain reducing Exparel product, which is expected at the end of October 2011.

In early August, Cathay Industrial Biotech, the largest private company in the HBM BioVentures portfolio, attempted an IPO on the US NASDAQ exchange at a valuation that would have been well above the book value of our investment. The turbulence on the equity markets at the time of the IPO attempt necessitated the postponement of these plans. Since Cathay operates cash-flow neutral, the company is not directly reliant on the proceeds of the IPO, and is able to evaluate other sources of financing to expand specific business areas.

Owing to the delays in the filing for approval of its primary drug, the valuation of PTC Therapeutics was reduced to the cost value of the investment. It had been valued higher for a time following an earlier financing round with a major investor at a higher valuation. Value adjustments were also necessary with regard to Interventional Spine and Cylene, because the difficult market environment in the orthopaedics sector has slowed sales growth at Interventional Spine, and because of the ultimate failure of Cylene's negotiations with possible strategic partners, which had dragged on into late summer. The investment in the oncology company Nereus was largely written off. CHF 5 million went into follow-on financing rounds connected with existing investments.

Investors continue to show an aversion to risk, so IPOs of portfolio companies will remain rare events. Significant increases in the value of individual investments are expected if clinical data are positive or products receive market approval.



Dr Andreas Wicki
CEO



Dr Joachim Rudolf
CFO

Consolidated Interim Financial Statements

Consolidated balance sheet

4

| | Notes | 30.9.2011 | 31.3.2011 |
|---|-------|----------------|----------------|
| Assets (CHF 000) | | | |
| Current assets | | | |
| Cash and cash equivalents | | 132,078 | 155,789 |
| Financial instruments | | 624 | 633 |
| Receivables | | 1,050 | 7,246 |
| Inventories | | 559 | 554 |
| Total current assets | | 134,311 | 164,222 |
| Non-current assets | | | |
| Investments | (2) | 390,746 | 450,953 |
| Other financial assets | (3) | 33,818 | 7,955 |
| Property, plant and equipment | | 227 | 187 |
| Intangible assets | | 4,951 | 5,010 |
| Total non-current assets | | 429,742 | 464,105 |
| Total assets | | 564,053 | 628,327 |
| Liabilities (CHF 000) | | | |
| Short-term liabilities | | | |
| Financial instruments | | 0 | 353 |
| Short-term financial liabilities | (4) | 29,940 | 36,166 |
| Other short-term liabilities | | 3,886 | 2,580 |
| Total short-term liabilities | | 33,826 | 39,099 |
| Long-term liabilities | | | |
| Long-term financial liabilities | (4) | 6,315 | 0 |
| Total long-term liabilities | | 6,315 | 0 |
| Shareholders' equity | | | |
| Share capital | (5) | 588,000 | 612,000 |
| Treasury shares | (5) | -24,198 | -26,257 |
| Capital reserve | | 375,326 | 369,019 |
| Currency translation differences | | 101 | 89 |
| Accumulated loss | | -415,317 | -365,623 |
| Total shareholders' equity | | 523,912 | 589,228 |
| Total liabilities and shareholders' equity | | 564,053 | 628,327 |
| Number of outstanding shares (in 000) | | 9,299 | 9,635 |
| Net asset value (NAV) per share (CHF) | | 56.34 | 61.15 |

Consolidated Interim Financial Statements

Consolidated statement of income

for the period 1 April to 30 September

| | Notes | Quarter ended 30.9.2011 | Quarter ended 30.9.2010 | 6-month period ended 30.9.2011 | 6-month period ended 30.9.2010 |
|--|-------|-------------------------|-------------------------|--------------------------------|--------------------------------|
| Result from investment activities (CHF 000) | | | | | |
| Gains on investments | (2) | 50,063 | 10,302 | 46,707 | 14,205 |
| Losses on investments | (2) | -58,327 | -43,134 | -77,953 | -64,492 |
| Result from currency hedging transactions | | -11,181 | 1,378 | -9,581 | 11,540 |
| Gains from other financial instruments | | 0 | 0 | 70 | 0 |
| Losses from other financial instruments | | -46 | 0 | 0 | 0 |
| Gains on other financial assets | | 6,813 | 160 | 1,318 | 1,533 |
| Losses on other financial assets | | 0 | -3,483 | -917 | -3,261 |
| Gross result from investment activities | | -12,678 | -34,777 | -40,356 | -40,475 |
| Result from product sales | | | | | |
| Revenues from product sales | | 38 | 34 | 73 | 88 |
| Costs of products sold | | -39 | -13 | -70 | -80 |
| Gross result from product sales | | -1 | 21 | 3 | 8 |
| Gross result | | -12,679 | -34,756 | -40,353 | -40,467 |
| Management fee | | -2,157 | -2,564 | -4,383 | -5,464 |
| Personnel expenses | | -629 | -712 | -1,276 | -1,605 |
| Other operating expenses | | -937 | -1,373 | -2,013 | -2,277 |
| Depreciation and amortisation | | -12 | -17 | -25 | -60 |
| Operating result before interest and taxes | | -16,414 | -39,422 | -48,050 | -49,873 |
| Financial income | | 25 | 3 | 93 | 16 |
| Financial expenses | | -856 | -969 | -1,736 | -2,157 |
| Result before taxes | | -17,245 | -40,388 | -49,693 | -52,014 |
| Income taxes | | 0 | 0 | -1 | 0 |
| Net result for the period | | -17,245 | -40,388 | -49,694 | -52,014 |
| Number of outstanding shares, time-weighted (in 000) | | 9,420 | 9,885 | 9,517 | 9,958 |
| Basic earnings per share (CHF) | | -1.83 | -4.08 | -5.22 | -5.22 |

As the Company does not have options or similar instruments outstanding, diluted earnings per share are identical to basic earnings per share.

Consolidated statement of comprehensive income

for the period 1 April to 30 September

| | Quarter ended 30.9.2011 | Quarter ended 30.9.2010 | 6-month period ended 30.9.2011 | 6-month period ended 30.9.2010 |
|---|-------------------------|-------------------------|--------------------------------|--------------------------------|
| (CHF 000) | | | | |
| Net result for the period | -17,245 | -40,388 | -49,694 | -52,014 |
| Contribution to operating result reported in shareholders' equity | | | | |
| Change owing to currency translation differences | -60 | 580 | 12 | 448 |
| Total comprehensive result | -17,305 | -39,808 | -49,682 | -51,566 |

Consolidated Interim Financial Statements

Consolidated statement of cash flows

for the period 1 April to 30 September

6

| (CHF 000) | 6-month period ended 30.9.2011 | 6-month period ended 30.9.2010 |
|--|-----------------------------------|-----------------------------------|
| Revenues from product sales received | 67 | 76 |
| Costs of products sold paid | -62 | -45 |
| Management fee paid | -4 383 | -5,464 |
| Other expenses paid (personnel and other operating expenses) | -3,344 | -3,768 |
| Net cash flow from operating activities | -7,722 | -9,201 |
| Interest payments received | 99 | 13 |
| Purchase of investments | -78,232 | -36,623 |
| Sale of investments | 83,178 | 53,131 |
| Payments received from escrow amounts and milestones | 5,428 | 2,551 |
| Net cash flow from financial instruments to hedge currency risks | -10,314 | 0 |
| Sale of other financial instruments | 458 | 0 |
| Purchase of property, plant and equipment | -84 | 0 |
| Net cash flow from investing activities | 533 | 19,072 |
| Interest paid on financial liabilities | -75 | -4,787 |
| Redemption of financial liabilities | 0 | -77,661 |
| Purchase of treasury shares | -17,715 | -15,435 |
| Sale of treasury shares | 2,081 | 2,714 |
| Net cash flow from financing activities | -15,709 | -95,169 |
| Currency translation differences | -813 | 137 |
| Net change in cash and cash equivalents | -23,711 | -85,161 |
| Cash and cash equivalents at beginning of period | 155,789 | 129,084 |
| Cash and cash equivalents at end of period | 132,078 | 43,923 |

Consolidated Interim Financial Statements

Consolidated statement of changes in equity

| | Share capital | Treasury shares | Capital reserve | Currency translations differences | Accumulated loss | Total shareholders' equity |
|--|----------------|-----------------|-----------------|-----------------------------------|------------------|----------------------------|
| (CHF 000) | | | | | | |
| Balance as at 31 March 2010 | 642,000 | -30,358 | 363,900 | -153 | -309,241 | 666,148 |
| Net result for the period | | | | | -52,014 | -52,014 |
| Currency translation differences | | | | 448 | | 448 |
| Total comprehensive result | | | | | | -51,566 |
| Purchase of treasury shares | | -15,435 | | | | -15,435 |
| Sale of treasury shares | | 3,625 | -911 | | | 2,714 |
| Capital reduction (3.9.2010) | -30,000 | 23,617 | 6,383 | | | 0 |
| Balance as at 30 September 2010 | 612,000 | -18,551 | 369,372 | 295 | -361,255 | 601,861 |
| Net result for the period | | | | | -4,368 | -4,368 |
| Currency translation differences | | | | -206 | | -206 |
| Total comprehensive result | | | | | | -4,574 |
| Purchase of treasury shares | | -11,024 | | | | -11,024 |
| Sale of treasury shares | | 3,318 | -353 | | | 2,965 |
| Balance as at 31 March 2011 | 612,000 | -26,257 | 369,019 | 89 | -365,623 | 589,228 |
| Net result for the period | | | | | -49,694 | -49,694 |
| Currency translation differences | | | | 12 | | 12 |
| Total comprehensive result | | | | | | -49,682 |
| Purchase of treasury shares | | -17,715 | | | | -17,715 |
| Sale of treasury shares | | 2,380 | -299 | | | 2,081 |
| Capital reduction (2.9.2011) | -24,000 | 17,394 | 6,606 | | | 0 |
| Balance as at 30 September 2011 | 588,000 | -24,198 | 375,326 | 101 | -415,317 | 523,912 |

Consolidated Interim Financial Statements

Notes

8

1. Summary of significant accounting policies

The consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) IAS 34 on Interim Financial Reporting and the provisions of the SIX Swiss Exchange Additional Rules on the Listing of Investment Companies. These interim financial statements should be read in conjunction with the consolidated financial statements for the financial year ended 31 March 2011, as they provide an update to the latest full financial report. In preparing the interim financial statements, the same accounting principles and methods of computation have been applied as in the preparation of the annual financial statements.

A summary of the new and revised IFRS/IAS standards and interpretations effective in the year under review is provided on page 51 of the Consolidated Financial Statements of the 2010/2011 Annual Report. The use of these standards had no impact on the financial condition or the earnings situation of the Company, or on its accounting principles.

The following conversion rates were used in the preparation of the financial statements:

| (CHF) | 30.9.2011 | 31.3.2011 |
|-------|-----------|-----------|
| DKK | 0.1634 | 0.1745 |
| EUR | 1.2158 | 1.3011 |
| GBP | 1.4153 | 1.4730 |
| SEK | 0.1321 | 0.1453 |
| USD | 0.9082 | 0.9190 |

2. Investments

Investments developed as follows during the reporting period:

| (CHF 000) | Private companies | Venture capital funds | Public companies | Total investments |
|---|-------------------|-----------------------|------------------|-------------------|
| Fair value as at 31 March 2011 | 267,450 | 100,123 | 83,380 | 450,953 |
| Purchases | 13,632 | 2,880 | 61,720 | 78,232 |
| Sales | -76,418 | -25,639 | -5,136 | -107,193 |
| Realised gains | 29,175 | 13,980 | 435 | 43,590 |
| Realised losses | -107,071 | -626 | -474 | -108,171 |
| Changes in unrealised gains | 113,538 | 3,650 | 9,153 | 126,341 |
| Changes in unrealised losses | -39,087 | -16,555 | -37,364 | -93,006 |
| Fair value as at 30 September 2011 | 201,219 | 77,813 | 111,714 | 390,746 |

Details on investments can be found on pages 11 and 12.

3. Other financial assets

The sale of a number of investment positions has given HBM BioVentures contractual claims to further purchase price payments that are contingent on the achievement of defined targets. These claims

are carried in the annual financial statements at a risk-weighted value, discounted over time (discount rate of 8-12 percent). The following summary shows the value carried in the balance sheet compared with the potential cash flows:

| (CHF million) | Book value as at 30.9.2011 | Range of possible cash flows, minimum | Range of possible cash flows, maximum | Expected period of payment |
|--------------------|-------------------------------|--|--|-------------------------------|
| ESBATEch | 7.2 | 0.0 | 54.1 | 2014–2018 |
| Mpex ¹⁾ | 11.4 | 5.9 | >41.6 | 2011–2029 |
| mtm laboratories | 18.8 | 5.8 | 31.6 | 2013–2016 |
| Other companies | 3.5 | 0.0 | 11.6 | 2012–2019 |
| Total | 41.0 | 11.7 | >138.9 | |

1) There is no ceiling on potential cash flows. The amount shown here is calculated on the basis of a cautious sales estimate.

Of the total book value as at 30 September 2011, CHF 33.8 million is carried under other financial assets (claims from investments held by HBM BioVentures directly). A further CHF 7.2 million is reported under investments, other private companies (claims from investments held indirectly via HBM BioCapital (EUR) L.P.).

If the companies concerned are successful, these contractual claims could result in future payments which are many times the reported book value.

ESBATEch

The company was acquired in September 2009 by Alcon Inc. The purchase price comprised an advance payment of USD 150 million, as well as a further USD 439 million in milestone payments that are tied to the achievement of clinical development targets. In addition to the advance, HBM BioVentures has to date received a small initial milestone payment. No further such payments are anticipated before 2014.

Mpex

The company was acquired in April 2011 by Axcen Pharma Inc. (now named Aptalis). Aptalis is paying the purchase price in cash – a guaranteed portion in tranches up to 2014, and the remainder as milestone payments contingent on market licensing and sales successes. HBM BioVentures will receive around USD 7 million in several tranches up to 2014. A further payment of approx. USD 8 million will fall due upon the registration and subsequent licensing of the AeroquinTM antibiotic. HBM BioVentures is also entitled to turnover-based payments on the

basis of product sales up to 2029. These may correspond to several times the current book value of the investment.

mtm laboratories

The company was acquired in July 2011 by Roche. The purchase price for the company of EUR 190 million comprised an advance payment of EUR 130 million and EUR 60 million as performance-based milestone payments. HBM BioVentures has received 90% of the advance payment. The remaining 10% will be released 18 and 60 months after completion of the transaction. The performance-related milestone payment is expected in 2014/2015.

Other companies

“Other companies” relates primarily to contractual claims from the sale of the investment holdings in Asthmatx, Adnexus and Syntonix, which are tied to sales growth, advances in clinical development and product approvals.

4. Financial liabilities

The following financial liabilities were outstanding within the HBM BioVentures Group as of the balance sheet date:

- > Debtor: HBM BioVentures Ltd.
Nominal CHF 30 million in straight bonds with a coupon of 10%, maturity 16 December 2011, redemption at 100% of par value.
- > Debtor: Tensys Medical Inc.
USD 6.9 million secured loan, including cumulated interest, interest rate 3.5% on the nominal value of USD 5 million, maturity 2 May 2015, convertible into 30% of outstanding shares of Tensys Medical Inc.

The loan to the Tensys Medical Inc. subsidiary was extended by four years in May 2011. The interest rate for the original nominal amount of USD 5 million was reduced from 10% p.a. to a new level of 3.5% p.a. At the same time, the lender was granted the right to convert the loan in to 30% of the outstanding shares of Tensys Medical Inc.

5. Equity capital

5.1 Share capital

As at the balance sheet date, the Company's share capital amounts to CHF 588 million, divided into 9,800,000 registered shares at a par value of CHF 60 each. The Ordinary Shareholders' Meeting of 24 June 2011 decided to reduce the Company's share capital by cancelling 400,000 treasury shares. The capital reduction was entered in the Commercial Register of the Canton of Zug on 2 September 2011.

5.2 Treasury shares

The Ordinary Shareholders' Meeting of 4 September 2009 authorised the Board of Directors to repurchase a maximum of 2,140,000 of the Company's own shares via a second trading line as part of a share buy-back programme lasting until 31 August 2012 at the latest and aimed at reducing capital ("Share buy-back programme 2009"). As part of this 2009 share buy-back programme, a total of 1,185,161 treasury shares were acquired, 500,000 of which were cancelled on 3 September 2010 and 400,000 on 2 September 2011 as part of the capital reduction. As at the balance sheet date of 30 September 2011, the Company held 285,161 of its own shares (31 March 2011: 349,311 own shares). In the 6-month period of the current financial year, a total of 335,850 of the Company's own shares were purchased via a second trading line at an average price of CHF 46.49.

Additionally, as at the balance sheet date of 30 September 2011, the HBM BioVentures (Cayman) Ltd. subsidiary holds 215,690 treasury shares (31 March 2011: 215,690 treasury shares), which have been purchased over the regular trading line. In the 6-month period until end of September 2011, a total of 45,614 treasury shares were purchased at an average price of CHF 46.08 per share (previous year: 103,653 treasury shares at CHF 43.65) and 45,614 treasury shares were sold at an average price of CHF 45.63 per share (previous year: 61,369 treasury shares at CHF 44.22) via the regular trading line. The loss of CHF 0.3 million (previous year: loss of CHF 0.9 million) from trading in treasury shares, which is reported in shareholders' equity, is based on the proceeds of shares sold minus the pro-rata average acquisition price of all shares purchased over the regular trading line.

6. Investment commitments

| (CHF 000) | 30.9.2011 | 31.3.2011 |
|-------------------------------------|---------------|---------------|
| HBM BioCapital (EUR) L.P. | 2,520 | 3,612 |
| Private companies | 4,497 | 1,349 |
| Venture capital funds | 15,816 | 18,911 |
| Total investment commitments | 22,833 | 23,872 |

7. Management fees

The annual management fee to HBM Partners amounts to 1.2 % of the Company assets plus 0.3% of the market capitalisation of the Company. In the 6-month period until end of September 2011, HBM Partners was paid CHF 4.4 million (previous year: CHF 5.5 million).

8. Transactions with related parties

HBM BioVentures holds an investment in the Hatteras Venture Partners III venture capital fund, where Robert A. Ingram, Member of the Board of Directors, serves as General Partner. For details on the investment commitment, paid-in capital and valuation, please refer to the overview of venture capital funds on page 12.

Investments

| | Domicile | Investment currency (IC) | Amount disbursed as at 31.3.2011 (IC m) | Changes in the reporting period (IC m) | Amount disbursed as at 30.9.2011 (IC m) | Fair value as at 30.9.2011 (IC m) | Ownership as % of portfolio company | Fair value as at 30.9.2011 (CHF 000) | Fair value as at 31.3.2011 (CHF 000) |
|--------------------------------------|-------------|--------------------------|---|--|---|-----------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|
| Private companies | | | | | | | | | |
| Cathay Industrial Biotech | China | USD | 28.0 | | 28.0 | 28.0 | 12.4% | 25,430 | 25,732 |
| PTC Therapeutics | USA | USD | 24.2 | | 24.2 | 24.2 | 10.0% | 21,981 | 35,988 |
| Lux Biosciences ¹⁾ | USA | USD | 19.2 | 1.4 | 20.6 | 20.6 | 15.0% | 18,749 | 17,646 |
| ChemoCentryx | USA | USD | 12.3 | | 12.3 | 17.2 | 7.4% | 15,579 | 15,764 |
| Ophthotech | USA | USD | 16.5 | | 16.5 | 16.5 | 16.9% | 14,947 | 15,125 |
| Nabriva Therapeutics ¹⁾ | Austria | EUR | 10.4 | 0.9 | 11.3 | 11.3 | 13.5% | 13,796 | 13,569 |
| Interventional Spine | USA | USD | 14.6 | 1.9 | 16.5 | 15.1 | 30.7% | 13,733 | 17,479 |
| Probiodrug | Germany | EUR | 13.7 | 0.7 | 14.3 | 6.3 | 9.7% | 7,647 | 7,338 |
| Medimpulse Holding | Switzerland | USD | 4.4 | | 4.4 | 8.3 | 20.7% | 7,533 | 7,622 |
| Ellipse Technologies ²⁾ | USA | USD | 0.0 | 8.0 | 8.0 | 8.0 | 24.7% | 7,269 | 0 |
| Cylene Pharmaceuticals | USA | USD | 12.2 | 0.7 | 12.9 | 7.9 | 10.1% | 7,189 | 11,212 |
| Enanta Pharmaceuticals | USA | USD | 7.7 | | 7.7 | 7.7 | 6.1% | 6,991 | 7,074 |
| Vivacta | UK | GBP | 3.9 | | 3.9 | 3.9 | 17.0% | 5,461 | 5,683 |
| Paratek Pharmaceuticals | USA | USD | 5.7 | | 5.7 | 5.0 | 3.1% | 4,567 | 4,621 |
| Cardiac Assist | USA | USD | 4.2 | | 4.2 | 4.2 | 9.1% | 3,797 | 3,842 |
| MiCardia ¹⁾ | USA | USD | 3.2 | 0.5 | 3.8 | 3.8 | 8.0% | 3,411 | 2,964 |
| Delenix Therapeutics ¹⁾ | Switzerland | CHF | 5.3 | | 5.3 | 2.9 | 18.8% | 2,871 | 2,871 |
| Westmed Holding | USA | USD | 5.5 | | 5.5 | 2.7 | 12.4% | 2,486 | 2,515 |
| Nereus Pharmaceuticals ¹⁾ | USA | USD | 14.5 | 1.0 | 15.5 | 0.2 | 9.2% | 205 | 7,957 |
| mtm laboratories ¹⁾³⁾ | Germany | EUR | 24.3 | -24.3 | 0.0 | 0.0 | 0.0% | 0 | 36,612 |
| Mpex Pharmaceuticals ¹⁾³⁾ | USA | USD | 13.4 | -13.4 | 0.0 | 0.0 | 0.0% | 0 | 9,526 |
| Other Investments | | | | | | | | 17,578 | 16,309 |
| Total private companies | | | | | | | | 201,219 | 267,450 |

1) As explained in Note 3 of the annual financial statements, this investment was made partly or wholly through HBM BioCapital (EUR) L.P. HBM BioCapital's pro rata fees are reimbursed in full to HBM BioVentures so that fees are not levied twice.

2) HBM BioVentures holds an additional approx. 6.1% stake in the company indirectly via the MedFocus Fund since August 2005.

3) The investment was sold during the period under review.


| | Domicile | Investment currency (IC) | Total commitment (IC m) | Payments in the reporting period (IC m) | Repayments in the reporting period (IC m) | Cumulative payments as at 30.9.2011 (IC m) | Cumulative repayments as at 30.9.2011 (IC m) | Fair value as at 30.9.2011 (IC m) | Fair value as at 30.9.2011 (CHF 000) | Fair value as at 31.3.2011 (CHF 000) |
|--------------------------------------|-------------|--------------------------|-------------------------|---|---|--|--|-----------------------------------|--------------------------------------|--------------------------------------|
| Venture capital funds | | | | | | | | | | |
| BioMedInvest I | Switzerland | CHF | 26.0 | | | 26.0 | 7.8 | 18.9 | 18,903 | 19,085 |
| Water Street Healthcare Partners | USA | USD | 15.0 | 0.2 | | 14.8 | 1.5 | 17.4 | 15,759 | 14,714 |
| MedFocus Fund II | USA | USD | 16.0 | | | 16.0 | 0.0 | 14.2 | 12,880 | 13,033 |
| Symphony Capital Partners | USA | USD | 15.0 | 0.1 | 0.5 | 14.7 | 7.4 | 5.9 | 5,400 | 4,883 |
| Galen Partners V | USA | USD | 10.0 | | | 5.4 | 0.0 | 5.4 | 4,876 | 4,389 |
| BioVeda China | China | USD | 8.5 | | 26.3 | 8.5 | 27.2 | 4.8 | 4,359 | 28,755 |
| Hatteras Venture Partners III | USA | USD | 10.0 | 0.7 | | 5.7 | 1.5 | 4.7 | 4,250 | 3,729 |
| BioMedInvest II | Switzerland | CHF | 10.0 | 2.0 | | 4.0 | 0.0 | 3.8 | 3,830 | 2,269 |
| Nordic Biotech | Denmark | DKK | 31.0 | | | 28.2 | 9.8 | 15.5 | 2,526 | 3,251 |
| EMBL Technology Fund | Germany | EUR | 2.1 | | | 2.1 | 0.0 | 1.7 | 2,098 | 2,020 |
| BioVentures Investors II | USA | USD | 3.0 | | | 3.0 | 0.5 | 1.1 | 987 | 993 |
| Heidelberg Innovation BSV II | Germany | EUR | 5.0 | | 0.3 | 5.0 | 1.2 | 0.6 | 757 | 1,258 |
| Skyline Venture Partners III | USA | USD | 3.0 | | 0.1 | 2.9 | 2.5 | 0.7 | 663 | 974 |
| A. M. Pappas LifeScience Ventures II | USA | USD | 3.0 | | 1.2 | 3.0 | 3.1 | 0.6 | 525 | 771 |
| Total venture capital funds | | | | | | | | | 77,813 | 100,123 |

| | Domicile | Investment currency (IC) | Number of shares as at 31.3.2011 | Changes in number of shares over the last 6 months | Changes in number of shares over the last 3 months | Number of shares as at 30.9.2011 | Ownership as % of portfolio company | Fair value as at 30.9.2011 (CHF 000) | Fair value as at 31.3.2011 (CHF 000) | |
|----------------------------------|---------------------------|--------------------------|----------------------------------|--|--|----------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|----------------|
| Public companies | | | | | | | | | | |
| Basilea Pharmaceutica | ^{P)} Switzerland | CHF | 665,038 | 1,061,341 | 634,507 | 1,726,379 | 18.0% | 67,156 | 44,026 | |
| Pacira Pharmaceuticals | ^{P)} USA | CHF | 3,137,597 | 0 | 0 | 3,137,597 | 18.2% | 28,296 | 20,473 | |
| Skye Pharma | UK | GBP | 4,976,806 | 0 | 0 | 4,976,806 | 20.8% | 3,830 | 3,006 | |
| Swedish Orphan Biovitrum | ^{P)} Sweden | SEK | 1,114,000 | 278,500 | 0 | 1,392,500 | 0.5% | 3,017 | 4,679 | |
| China Nuokang Biopharmaceuticals | ^{P)} China | USD | 355,652 | 0 | 0 | 355,652 | 1.8% | 1,541 | 1,503 | |
| Other investments | | | | | | | | 7,874 | 9,694 | |
| Total public companies | | | | | | | | | 111,714 | 83,380 |
| Total investments | | | | | | | | | 390,746 | 450,953 |

P) The position originates from the private companies portfolio.

Net asset value (NAV) and shares of HBM BioVentures Ltd versus market

in Swiss francs, indices indexed (12.7.2001 = 100)



Significant shareholders

Based on the notifications received by the Company, the following shareholders are known to hold 3 percent or more of the share capital of HBM BioVentures as at 30 September 2011:

| Shareholder | Latest notification of shareholding | Published on |
|--|-------------------------------------|--------------|
| Astellas Pharma Inc. | 11.04% | 7.4.2011 |
| HBM BioVentures Ltd (treasury shares) | 5.11% | 30.9.2011 |
| Alpine Select Ltd/ Daniel Sauter | 5.11% | 31.3.2011 |
| BVK Personalvorsorge des Kantons Zürich | 3.92% | 12.2.2008 |

Information on shares

| | |
|---------------------------|------------------------|
| Swiss security number | 1.262.725 |
| German security number | 984345 |
| ISIN | CH 0012627250 |
| CUSIP | H 3553X112 |
| Telekurs | 126,126272 |
| SIX Swiss Exchange Ticker | HBMN |
| Internet | www.hbmbioventures.com |

This Quarterly Report is published in English and German. The German version is binding in all matters of interpretation.

Board of Directors

Hans Peter Hasler, Chairman
 Prof. Dr Dr h.c. mult. Heinz Riesenhuber¹⁾, Vice Chairman
 Dr Eduard E. Holdener
 Robert A. Ingram²⁾
 Dr Rudolf Lanz¹⁾²⁾
 Dr Dr h.c. Henri B. Meier, Honorary Chairman
 Dr Benedikt Suter, Secretary of the Board of Directors

1) Member of the Audit Committee
 2) Member of the Nominating Committee

Management

Dr Andreas Wicki, Chief Executive Officer
 Dr Joachim Rudolf, Chief Financial Officer

Fees

Annual management fee:
 1.2% of Company assets plus
 0.3% of the Company's market capitalisation
 High water mark per share
 for all outstanding shares NAV of CHF 107.71

